Related by context. All words. (Click for frequent words.) 69 statistically significant improvement 68 statistically significant 63 primary endpoint 63 clinically meaningful improvement 62 placebo p = 62 clinically meaningful reductions 61 primary efficacy endpoint 61 #mg/day [001] 61 statistically significant differences 61 mcg BID 61 P = .# 61 tapentadol ER 60 statistically significant p 60 nonsignificant 60 CIMZIA TM certolizumab pegol 60 clinically meaningful 60 secondary endpoints 60 oxycodone CR 60 achieved statistical significance 60 placebo p 60 secondary endpoint 60 tipranavir r 59 mg dose 59 headache nasopharyngitis 59 ropivacaine 59 plus methotrexate 59 desvenlafaxine succinate 59 placebo 59 #mg BID [001] 59 p = #.# [002] 59 #mg BID [003] 59 clinically meaningful improvements 58 mcg QD 58 achieved ACR# 58 severe exacerbations 58 DAS# CRP 58 composite endpoint 58 insulin detemir 58 binary restenosis 58 Rating Scale MADRS 58 timepoint 58 ATACAND 58 rosuvastatin #mg 58 p = #.# [004] 58 lumbar spine BMD 58 Cmax 58 FOLFOX6 57 statistically significant p = 57 nadolol 57 salmeterol fluticasone 57 HBeAg seroconversion 57 mg kg dose 57 mg QD 57 4mg/kg 57 #.#/#.# mmHg [001] 57 nonfatal MI 57 LEXIVA r 57 lopinavir r arm 57 CIMZIA ™ 57 Psoriasis Area 57 undetectable HBV DNA 57 morphometric vertebral fractures 57 statin monotherapy 57 gastrointestinal perforation 57 transaminases 57 p = NS 56 gross hematuria 56 FFNS 56 CSBM 56 pooled comparator 56 lispro 56 MADRS score 56 Secondary endpoints included 56 bronchodilatory 56 tirofiban 56 p = .# [002] 56 reinfarction 56 mcg kg 56 CIMZIA TM 56 SVR# 56 rotigotine 56 macroalbuminuria 56 inflammatory lesions 56 fractional shortening 56 atazanavir ritonavir 56 HBeAg negative patients 56 #mg dose [003] 56 n = 56 thromboembolic events 56 ibandronate 56 non inferiority 56 mg TID 56 serum urate levels 56 aspartate aminotransferase AST 56 pretreatment baseline 56 symptomatic VTE 56 statistical significance 56 plasma concentrations 56 TEAEs 56 efficacy endpoint 56 demonstrated statistically significant 56 bronchodilation 56 ventricular tachyarrhythmia 56 MCyR 56 Secondary endpoints 55 dobutamine 55 bolus injection 55 highest tertile 55 maximal tolerated 55 μg kg 55 placebo controlled clinical 55 transaminase elevations 55 teriflunomide 55 tolterodine ER 55 nondiabetic patients 55 dose dependently 55 severe hypoglycemic 55 rimonabant #mg 55 eplerenone 55 primary endpoints 55 elevated ALT 55 nausea photophobia 55 neurologic progression 55 chlorambucil 55 mg ustekinumab 55 lowest tertile 55 APTIVUS r 55 budesonide pMDI 55 log# 55 octreotide LAR 55 hypoglycemic events 55 p = 55 zonisamide SR 55 fraction LVEF 55 8mg/kg 55 VAPRISOL 55 ACR# response 55 Hypotension 55 PASI scores 55 tiotropium 55 somatostatin analog 55 pegylated liposomal doxorubicin 55 #mg doses [002] 55 isoproterenol 55 5mg/kg 55 serum phosphorus 55 GOUT 55 baseline PASI 55 myocardial infarctions 55 S/GSK# 55 certolizumab 55 virologic breakthrough 55 mg BID 55 MACCE 55 nab paclitaxel 55 ipsilateral stroke 55 multivariate adjustment 55 #mg QD [001] 55 extrapyramidal symptoms 54 dapagliflozin plus 54 Pharmacokinetic studies 54 NIH CPSI 54 achieving PASI 54 #mg/day [002] 54 creatinine ratio 54 MADRS 54 tumor regressions 54 seropositive patients 54 virologic response 54 #.#mg/dL 54 alanine aminotransferase 54 steroid dexamethasone 54 ARCOXIA 54 aspartate aminotransferase 54 elevated transaminases 54 RoACTEMRA 54 elevated creatinine 54 QTcF 54 nicardipine 54 non menstrual pelvic 54 lanthanum carbonate 54 tolvaptan 54 Primary endpoints 54 enoximone 54 AUC0 54 serum urate 54 apremilast 54 nadroparin 54 CR CRu 54 doxorubicin docetaxel 54 hour bronchodilation 54 log# reduction 54 leuprorelin 54 mucosal healing 54 ribavirin RBV 54 recurrent ischemia 54 mL kg 54 liver transaminases 54 IPSS 54 systemic hypotension 54 linaclotide treated 54 lenalidomide dexamethasone 54 HBeAg positive 54 #mg/kg [002] 54 ALVESCO 54 secondary efficacy endpoints 54 Subgroup analysis 54 serum parathyroid hormone 54 β blocker 54 oral rivaroxaban 54 complete cytogenetic response 54 experimentally induced 54 serum triglycerides 54 tapentadol IR 54 CCyR 54 AZILECT 54 nasopharyngitis headache 54 BARACLUDE ® 54 unresectable HCC 54 mg kg 54 INC# 54 NEVO ™ 54 ABC/3TC 54 secondary efficacy endpoint 54 Fasting plasma glucose 54 thromboembolic 54 incontinence episodes 54 statistically significant superiority 54 noninferiority 54 Subgroup analyzes 54 detrusor 54 racemic albuterol 54 solifenacin 54 diameter stenosis 54 6MWD 54 1mg dose 54 lopinavir r 54 pharmacodynamic PD 54 TMC# r 54 valsartan 54 active comparator 54 sUA 54 oral antidiabetic medication 54 receiving ISENTRESS 54 % CI #.#-#.# [007] 53 lumbar spine bone 53 p ≤ 53 angiographic outcomes 53 REYATAZ r arm 53 cardiovascular calcification 53 oral allopurinol 53 IIIa inhibitor 53 annualized relapse 53 β blockers 53 methotrexate monotherapy 53 plasma pharmacokinetics 53 mcg kg REBETOL 53 periprocedural 53 LV dysfunction 53 insulin degludec 53 prespecified 53 Kaplan Meier analysis 53 CANCIDAS 53 tertile 53 glycated hemoglobin HbA1c 53 oral diclofenac 53 VT VF 53 tegaserod 53 administered subcutaneously 53 RAPAFLO R 53 biphasic insulin aspart 53 edoxaban 53 adjunctive placebo 53 experienced virologic failure 53 plasma HCV RNA 53 achieved CCyR 53 sirolimus eluting stent 53 amprenavir 53 mcg albinterferon alfa 2b 53 Patency 53 confidence interval CI 53 methacholine challenge 53 discontinuations due 53 zolmitriptan 53 tipranavir 53 glycosylated hemoglobin HbA1c 53 CNS LS 53 irbesartan 53 GERD symptom 53 FEV1 forced expiratory 53 pharmacokinetic equivalence 53 receiving APTIVUS r 53 vasodilatory 53 CR nPR 53 Crohn Disease Activity 53 Montgomery Asberg Depression 53 intravascular hemolysis 53 #mg/m# [001] 53 mg BID dose 53 dose proportionality 53 spontaneous bowel movements 53 ZOMIG Nasal Spray 53 glycoprotein IIb IIIa inhibitor 53 caspofungin 53 TDF FTC 53 mean baseline HbA1c 53 PANSS scores 53 cerebrovascular events 53 FOLPI 53 ug dose 53 bosentan 53 nmol liter 53 DAPT 53 nasal symptom 53 ADCS CGIC 53 QTc intervals 53 reach statistical significance 53 plus gemcitabine 53 serum phosphate 53 LPV r 53 serum potassium 53 median PFS 53 HBeAg 53 dexmedetomidine 53 Thal Dex 53 IOP lowering 53 dose cohort 53 statistically significant predictor 53 % CI #.#-#.# [003] 53 partial remissions 53 parkinsonian symptoms 53 otamixaban 53 #mg QD [002] 53 analgesic efficacy 53 3mg/kg 53 hypercalcemia 53 recurrent DVT 53 Xalatan R 53 ug kg 53 arterial thromboembolic events 53 olmesartan 53 receiving golimumab 53 subcutaneous insulin 53 monotherapy 53 Score TOS 53 #.#g/day 53 % CI #.#-#.# [002] 53 Brief Psychiatric 53 PRADAXA #mg 53 dyspnea 53 bolus dose 53 Scale PANSS 53 mg RDEA# 53 serum leptin 53 serum phosphorous 53 ischemia driven 53 #mg BID [002] 53 clinically relevant 53 LEXIVA 53 Index CDAI 53 infarct size 53 Target Lesion Revascularization TLR 53 comparator arm 53 #mg dose [001] 53 recurrent glioblastoma multiforme 53 neutropenia thrombocytopenia 53 inhaled iloprost 53 correlated inversely 53 Plasma concentrations 53 apnea hypopnea index 53 postprocedure 53 posaconazole 53 locomotor activity 53 fluticasone salmeterol 53 Negative Syndrome 53 abacavir lamivudine 53 subcutaneous dose 53 statistically nonsignificant 53 HIV RNA 53 ACR# responses 53 MEND CABG 53 ACTEMRA TM 53 elagolix 53 HF hospitalization 52 adefovir 52 risperidone Risperdal 52 fosbretabulin 52 sustained virologic response 52 oxycodone IR 52 bivalirudin monotherapy 52 ≥ 52 mg qd 52 nasopharyngitis 52 rolofylline 52 urate lowering 52 Scale EDSS 52 CI -#.# 52 atorvastatin #mg 52 intermittent dosing 52 colesevelam HCl 52 pramipexole 52 virologic failure 52 severe hypoglycemia 52 acute coronary syndromes ACS 52 bupivacaine 52 serologically active SLE 52 plus OBT 52 #mmHg [001] 52 elevated troponin 52 OADs 52 μg mL 52 Persistent Sleep 52 segment binary restenosis 52 patients evaluable 52 #ug [001] 52 Montgomery Åsberg Depression 52 plus dexamethasone 52 CC genotype 52 ritonavir boosted 52 rapid virologic response 52 mg d 52 peginterferon alfa 2b 52 PSA nadir 52 lymphocyte counts 52 abdominal pain abdominal discomfort 52 paricalcitol 52 anemia hemoglobin 52 endometrial thickness 52 serum concentrations 52 NLX P# 52 hypophosphatemia 52 HBeAg positive patients 52 corrected QT interval 52 ALT normalization 52 systolic BP 52 virological response 52 coronary artery occlusion 52 left ventricular LV 52 definite stent thrombosis 52 nodular partial response 52 riociguat 52 noninferior 52 primary efficacy endpoints 52 complete remissions 52 quetiapine 52 XIENCE V PROMUS Stent 52 mirtazapine 52 serum phosphate levels 52 unfractionated heparin UFH 52 statistical significance p 52 evaluable patients 52 adalimumab 52 fluvastatin 52 intracoronary 52 severe hypersensitivity reactions 52 mg Lucentis 52 univariate analysis 52 alicaforsen enema 52 FOLFOX4 52 colorectal adenoma 52 serum uric acid 52 trastuzumab Herceptin ® 52 phonophobia 52 plasma leptin 52 FEV1 52 IL 1ß 52 log# copies mL 52 pulmonary arterial 52 AGILECT R 52 Symptom severity 52 clevidipine 52 concomitant antibiotics 52 ramipril 52 deep venous thromboses 52 intraperitoneal 52 mL/min/#.# m 2 52 mg p = 52 seroprotection 52 intradermal injections 52 log# IU mL 52 NIHSS 52 timepoints 52 % CI #.#-#.# [006] 52 XIENCE V demonstrated 52 LV ejection fraction 52 limiting toxicity 52 SSRI citalopram 52 visceral metastases 52 hemoglobin A1c HbA1c 52 RE LY trial 52 RECIST Response Evaluation Criteria 52 brivaracetam 52 NPH insulin 52 hyperphenylalaninemia HPA due 52 fluticasone furoate 52 mecamylamine 52 laxation 52 aminotransferases 52 systemic embolism 52 pharmacokinetics PK 52 prospectively defined 52 plasma lipids 52 sustained virological response 52 myocardial infarction stroke 52 ximelagatran 52 fondaparinux 52 -#.# ± [002] 52 evaluable 52 rFVIIa 52 PEGylated anti 52 viral kinetics 52 alanine aminotransferase ALT 52 selective modulator 52 progression TTP 52 opioid naïve 52 QD dosing 52 achieve statistical significance 52 systolic dysfunction 52 Darusentan 52 left ventricular dysfunction 52 recurrent venous thromboembolism 52 Thrombolysis 52 SCIg 52 relapsed MM 52 Visual Analogue Scale VAS 52 Severity Index PASI 52 creatine kinase 52 cis retinoic acid 52 #mm Hg 52 normotensive 52 ezetimibe simvastatin 52 efficacy endpoints 52 Phase 2a trial 52 postintervention 52 clomipramine 52 micafungin 52 weekly subcutaneous injections 52 pegaptanib 52 plus octreotide LAR 52 #μg [002] 52 cinacalcet 52 Tolvaptan 52 retinal thickness 52 estramustine 52 viral kinetic 52 stent binary restenosis 52 highly emetogenic 52 moderate renal impairment 52 inotropic 52 EUFLEXXA R 52 CTEPH 52 LEVADEX 52 baseline HbA1c 52 placebo controlled 51 zoledronate 51 NATRECOR ® 51 EDARBI 51 idraparinux 51 PREZISTA r arm 51 mmHg diastolic 51 plus MTX 51 sumatriptan naproxen sodium 51 evaluable subjects 51 pg mL 51 baminercept 51 Hb A1C 51 VP# [004] 51 undetectable HCV RNA 51 certolizumab pegol 51 rizatriptan 51 μmol L 51 detrusor overactivity 51 NYHA functional class 51 natriuresis 51 exacerbations 51 mcg mL 51 Ereska 51 ARCALYST ® 51 bezafibrate 51 GSK# [001] 51 crizotinib PF # 51 inverse association 51 leukopenia 51 LVEF 51 PEG IFN 51 eosinophilic asthma 51 LT NS# 51 primary hypercholesterolemia 51 candesartan cilexetil 51 mmol l 51 Secondary endpoints include 51 GRNCM1 51 mitoxantrone plus 51 myocardial infarction MI 51 darbepoetin alpha 51 ruboxistaurin 51 icatibant 51 prednisone prednisolone 51 receiving INTRON 51 TIMI 51 YMRS 51 -#.# mg dL [002] 51 catheter occlusion 51 serum uric acid sUA 51 favorable tolerability 51 tiotropium bromide 51 Betaferon ® 51 fasting plasma glucose FPG 51 dexamethasone 51 Pharmacokinetic 51 total cholesterol triglycerides 51 transaminase 51 coadministration 51 ULORIC 51 mcg doses 51 AUA Symptom Score 51 mEq L 51 #mg dosing group 51 rt PA 51 etanercept 51 DOXIL 51 epoetin alpha 51 oxcarbazepine 51 thrombocytopenic 51 -#.# mg dL [001] 51 PREZISTA r 51 TAXUS Stent 51 #mg/m# [002] 51 mild renal impairment 51 response CCyR 51 ‰ ¥ 51 BENICAR 51 double blinded placebo 51 non valvular atrial 51 non splenectomized 51 anagrelide 51 Torsades de Pointes 51 QTc prolongation 51 subanalysis 51 mITT population 51 Free Survival PFS 51 placebo controlled clinical trials 51 fasting triglycerides 51 urate lowering therapy 51 PLX STROKE targeting 51 CrCl 51 sd = 51 febrile neutropenia 51 darunavir ritonavir 51 bronchial hyperresponsiveness 51 eszopiclone 51 dalteparin 51 NATRECOR R 51 pg ml 51 mild renal insufficiency 51 pegylated interferon peg IFN 51 intra articular injection 51 lymphopenia 51 MoxDuo TM IR 51 mg Proellex 51 intima media thickness 51 unfractionated heparin 51 serum cortisol 51 aminotransferase ALT 51 hyperacute 51 Pegasys plus Copegus 51 leucopenia 51 postoperatively 51 PANSS total 51 pharmacodynamic effects 51 antiretroviral naive 51 diastolic blood pressures 51 posttreatment 51 placebo dexamethasone 51 upper gastrointestinal bleeding 51 prolonged QT interval 51 Acute Ischemic Stroke 51 μg 51 glycated hemoglobin levels 51 systemic corticosteroid 51 adenoma recurrence 51 plasma folate 51 pulmonary capillary wedge 51 Unified Parkinson Disease 51 Events MACE 51 daily subcutaneous injections 51 RAPTIVA 51 iloprost 51 adriamycin 51 DAS# remission 51 pulmonary artery pressure 51 TRITON TIMI 51 Solid Tumors criteria 51 HbA 1c 51 remifentanil 51 Flu Cy 51 Visual Analog Scale 51 ejection fractions 51 Engerix B 51 serum sodium levels 51 locoregional recurrence 51 salmeterol fluticasone propionate 51 statistically significant correlations 51 FluCAM 51 cardiovascular hospitalizations 51 intraocular inflammation 51 dyspareunia 51 milrinone 51 mapatumumab 51 myocardial ischemia 51 QTc 51 nephrotoxicity 51 confidence interval #.#-#.# 51 moderate hepatic impairment 51 ertapenem 51 Major Adverse Cardiac 51 Navelbine 51 AEGR 51 Postoperative 51 AST ALT 51 dose limiting toxicities 51 kilogram mg kg 51 malignancy HCM 51 urinary albumin 51 ischemic cardiomyopathy 51 Pharmacokinetics PK 51 antipsychotic efficacy 51 vaginal progesterone gel 51 palonosetron 51 % Confidence Interval 51 xanthine oxidase inhibitor 51 recurrent atrial fibrillation 51 DAS# [002] 51 hip BMD 51 BUPHENYL 51 5-FU/LV 51 Elitek 51 IFN alfa 51 Acetate Rectal Suppositories 51 RESIST studies 51 zoledronic acid 51 clazosentan 51 iPTH 51 ADAGIO study 51 systolic diastolic blood 51 angiotensin converting enzyme inhibitors 51 piperacillin tazobactam 51 alteplase 51 Univariate analysis 51 randomized controlled 51 Abbott HUMIRA 51 Erythropoietic therapies may 51 bacteriuria 51 nocturnal awakenings 51 CRp 51 ADAS Cog 51 lactate dehydrogenase 51 ATV RTV 51 % CI #.#-#.# [008] 51 ACZ# 51 MBq 51 ticagrelor 51 HbA 1c levels 51 briakinumab 51 fosamprenavir 51 pomalidomide 51 HCV RESPOND 2 51 paresthesias 51 surgically resected 51 TAXUS p value 51 L PPDS 51 Aptivus ® 51 oral Hycamtin 51 VIIBRYD 51 elevated prolactin 51 neurologic dysfunction 51 rabeprazole 51 hemodynamically significant 51 abciximab 51 intravenous dosing 51 oral FTY# 50 detemir 50 Doxil ® 50 HMG CoA reductase inhibitors 50 ramelteon 50 rilonacept 50 aprepitant 50 hepatocellular 50 pioglitazone 50 mg doses 50 squamous histology 50 endoscopic remission 50 simvastatin ezetimibe 50 pharmacodynamics PD 50 Mg Uk 50 pamidronate 50 ziprasidone 50 rufinamide 50 hemorrhagic complications 50 NYHA Class II 50 atheroma volume 50 rhTSH 50 titrated glipizide 50 specific antigen PSA 50 Secondary efficacy endpoints 50 nonrandomized 50 ACR# ACR# 50 scores TNSS 50 PEG Intron 50 saline placebo 50 mg eq 50 genotypic resistance 50 subcutaneously administered 50 GnRH agonist 50 NYHA Class III 50 mitoxantrone 50 ventricular remodeling 50 sinus rhythm 50 invasive carcinomas 50 tamsulosin 50 attain statistical significance 50 Ramipril 50 febuxostat 50 PREZISTA ritonavir 50 multicenter placebo controlled 50 CDAI 50 virologic 50 RLAI 50 HIV HCV coinfected 50 pravastatin therapy 50 PaO 2 50 favorable pharmacokinetic profile 50 HOMA IR 50 fluticasone 50 UPDRS motor 50 NSTE ACS 50 Pred Forte 50 nonfatal stroke 50 enalapril 50 #mg #mg #mg [003] 50 mCRC patients 50 ACR# [002] 50 GIK infusion 50 antiarrhythmic 50 coronary stenosis 50 triiodothyronine 50 intravesical 50 x ULN 50 placebo fluoxetine 50 flow mediated dilation 50 mg administered orally 50 statistically significant correlation 50 microgram kg 50 erythropoietic 50 Pain Intensity 50 g dL 50 interquartile range 50 nonfatal myocardial infarction 50 asystole 50 MabCampath 50 glycosylated hemoglobin 50 degarelix 50 creatinine clearance 50 octreotide 50 tertiles 50 BENICAR HCT 50 MERLIN TIMI 50 apolipoprotein B 50 acromegalic patients 50 mg/m2 dose 50 dose titration 50 prospective multicenter randomized 50 subcutaneous enoxaparin 50 min -1 50 hepatic enzyme 50 ketorolac 50 Mean Symptom Complex 50 pyridostigmine 50 intravesical therapy 50 distension 50 euthymic patients 50 IV bolus 50 hematologic toxicity 50 splenectomized patients 50 stent thromboses 50 adalimumab Humira 50 heavily pretreated 50 IELT 50 mg simvastatin 50 QNEXA 50 CVD mortality 50 alvimopan 50 doxorubicin cyclophosphamide 50 #mg dose [002] 50 #.#/#.# mm Hg [003] 50 thromboembolism 50 hypercalcaemia 50 logistic regression analysis 50 locoregional disease 50 carotid intima media 50 prucalopride 50 temsirolimus 50 clodronate 50 chronic angina 50 Natalizumab 50 ml min 50 plasma uric acid 50 cerebral oxygenation 50 syncope fainting 50 lacosamide 50 UPDRS 50 vasopressor 50 peg interferon 50 hypokalemia 50 serum IGF 50 alanine transaminase 50 beclomethasone dipropionate 50 Folfox 50 biochemical relapse 50 retrograde ejaculation 50 dysuria 50 splenectomized 50 ventricular dilatation 50 alpha 2a 50 ventricular enlargement 50 fructosamine 50 dose Iluvien 50 anemia leukopenia 50 CK MB 50 invasive aspergillosis 50 Pharmacokinetic parameters 50 HbA1C levels 50 cytogenetic response 50 EDEMA3 trial 50 ALGRX 50 cytopenias 50 IFN α 50 telmisartan 50 VaD 50 plasma cortisol 50 Capesaris 50 iodixanol 50 corticosteroid dose 50 interferon alfa 2b 50 #.#mmol L [002] 50 receptor blocker 50 hemodilution 50 Durezol 50 mg tid 50 MIRAPEX 50 pCR 50 endometrial hyperplasia 50 #OHD levels 50 trials RCTs 50 highest quintile 50 uM 50 fatigue asthenia 50 cisplatin vinorelbine 50 hemoglobin concentration 50 BUPHENYL R sodium phenylbutyrate 50 μg dose 50 avosentan 50 apnea hypopnea 50 stage IIIb IV 50 nonexposed 50 ABSORB trial 50 nonsignificant difference 50 maximally tolerated dose 50 troponin T 50 RezularTM 50 mmol L 50 depressive symptom 50 Hp2 2 50 potentiation 50 STRIDE PD 50 elevated liver enzymes 50 Ophena TM 50 blood phenylalanine Phe 50 aldosterone antagonists 50 posttransplant 50 Solid Tumours 50 salmeterol HFA MDI 50 somatic symptom 50 Response Evaluation Criteria 50 cilostazol 50 benazepril 50 aspirin clopidogrel 50 oral levofloxacin 50 detectable HCV RNA 50 BMI z 50 teduglutide 50 DES implantation 50 SPIRIT FIRST 50 MAP# 50 CLARITY study 50 refractory ischemia 50 Traficet EN 50 pentoxifylline 50 RE LY ®